Integra LifeSciences (NASDAQ:IART) Given New $22.00 Price Target at Citigroup

Integra LifeSciences (NASDAQ:IART - Free Report) had its target price boosted by Citigroup from $16.00 to $22.00 in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a sell rating on the life sciences company's stock.

Other equities research analysts have also recently issued reports about the company. Bank of America dropped their price target on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a report on Monday, October 7th. Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, October 14th. BTIG Research raised shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a report on Monday, October 7th. JMP Securities dropped their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating for the company in a research report on Tuesday, July 30th. Finally, Morgan Stanley lifted their target price on Integra LifeSciences from $24.00 to $27.00 and gave the company an "underweight" rating in a research note on Monday, July 15th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $27.25.

Integra LifeSciences Price Performance

Shares of IART stock traded up $0.79 during trading hours on Tuesday, hitting $24.91. The company had a trading volume of 1,746,243 shares, compared to its average volume of 1,101,824. Integra LifeSciences has a 12 month low of $16.81 and a 12 month high of $45.42. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. The firm's fifty day moving average is $18.68 and its 200 day moving average is $24.41. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of 83.97, a PEG ratio of 0.66 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to analysts' expectations of $375.81 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The business's revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.76 earnings per share. On average, sell-side analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds have recently added to or reduced their stakes in the stock. Capital Research Global Investors grew its holdings in Integra LifeSciences by 37.7% during the first quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company's stock valued at $209,828,000 after purchasing an additional 1,621,655 shares during the period. Jane Street Group LLC grew its holdings in shares of Integra LifeSciences by 181.1% in the 1st quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company's stock valued at $4,427,000 after buying an additional 80,463 shares during the period. SG Americas Securities LLC increased its position in shares of Integra LifeSciences by 606.9% in the 2nd quarter. SG Americas Securities LLC now owns 67,471 shares of the life sciences company's stock valued at $1,966,000 after buying an additional 57,927 shares in the last quarter. Boston Partners acquired a new stake in Integra LifeSciences during the 1st quarter worth $19,383,000. Finally, Nordea Investment Management AB lifted its holdings in Integra LifeSciences by 16.0% during the first quarter. Nordea Investment Management AB now owns 110,695 shares of the life sciences company's stock worth $3,840,000 after acquiring an additional 15,244 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.